Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Amarin Corporation plc (AMRN)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.2000+0.0300 (+2.56%)
At close: 04:00PM EST
1.2000 0.00 (0.00%)
After hours: 05:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
MACD

MACD

Previous Close1.1700
Open1.1900
Bid1.1600 x 28000
Ask1.2000 x 45100
Day's Range1.1400 - 1.2000
52 Week Range1.0400 - 3.8200
Volume4,540,604
Avg. Volume2,728,544
Market Cap484.595M
Beta (5Y Monthly)1.78
PE Ratio (TTM)N/A
EPS (TTM)-0.0560
Earnings DateOct 27, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-12% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for AMRN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Amarin Corporation plc
    EXEL: What does Argus have to say about EXEL?EXELIXIS INC has an Investment Rating of HOLD; a target price of $18.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
    Rating
    Fair Value
    Economic Moat
    8 days agoArgus Research
View more
  • GlobeNewswire

    Amarin Announces VAZKEPA® (icosapent ethyl) Receives Regulatory Approval in Switzerland

    -- Amarin Continuing Process for Obtaining National Pricing and Reimbursement in Switzerland in the Course of 2023 -- -- Swissmedic Approval Underpins Company’s Presence and Expansion in Switzerland as its Regional Commercial Hub for Europe -- DUBLIN, Ireland and BRIDGEWATER, N.J., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Switzerland’s Swissmedic has granted approval to VAZKEPA (icosapent ethyl). Swissmedic approved VAZKEPA to reduce risk of car

  • Zacks

    Why Amarin (AMRN) Stock Might be a Great Pick

    Amarin (AMRN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

  • Motley Fool

    Why Amarin Stock Was a Winner Today

    Before market open, Amarin announced that its Vazkepa (brand-named Vascepa in the U.S.) has been approved by Australia's Therapeutic Good Administration (TGA). Amarin didn't hesitate to mention that the Australian nod represents the fifth regulatory approval for Vazkepa/Vascepa. Among these jurisdictions are the U.S. and the European Union, which consists of 27 countries on that continent.

Advertisement
Advertisement